---
title: "Dermata Therapeutics, Inc. (DRMA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DRMA.US.md"
symbol: "DRMA.US"
name: "Dermata Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T07:41:00.712Z"
locales:
  - [en](https://longbridge.com/en/quote/DRMA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DRMA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DRMA.US.md)
---

# Dermata Therapeutics, Inc. (DRMA.US)

## Company Overview

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.dermatarx.com](https://www.dermatarx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.67 | 156 | - | - | - |
| PB | 0.74 | 66 | 0.84 | 0.63 | 0.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.18 |
| Highest Target | 4.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DRMA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DRMA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DRMA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DRMA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**